Vyvanse - 2007 FDA approvals

Drug: Vyvanse (lisdexamfetamine dimesylate)width=169
Indication: ADHD
Company: New River Pharmaceuticals
Approval Date: 23-Feb-2007

Scoop: Vyvanse is amphetamine based, but only becomes effective after it enters the digestive tract. The company says that the digestive trigger mechanism should make the drug less liable for abuse by users who snort or inject pills.

More news:
FDA hands out two key regulatory approvals. Report

Vyvanse - 2007 FDA approvals
Read more on

Suggested Articles

Karen DeSalvo's appointment is the latest in a string of hires that deepen the tech giant’s investment in and focus on healthcare.

Spring Bank’s hepatitis B drug, given in tandem with Gilead’s Vemlidy, tamped down on chronic disease in 23% of patients in a phase 2 study.

Verseau will use the money to start testing its macrophage checkpoint modulators in humans.